Company news

Spruce Biosciences, Inc. (NASDAQ:SPRB) news

Spruce Biosciences, Inc. news releases on 6ix. Latest, Sep 8, 2026: Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment…

Spruce Biosciences, Inc. (NASDAQ:SPRB) news

Press releases & updates

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Spruce Biosciences Announces Launch of MPS3BStudy.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Spruce Biosciences Joins the Russell 3000® Index

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces $50.0 Million Private Placement Financing

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Reverse Stock Split

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH